CSNK1E and marginal zone lymphoma: Umbralisib (UKONIQTM; TGR-1202; TG Therapeutics) is a dual PI3Kδ and casein kinase 1 epsilon (CK1ε) inhibitor with accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and refractory FL who have received at least three prior lines of systemic therapy on 2021 (Dhillon and Keam 2021).